Comparison of locus-specific databases for  and  variants reveals disparity in variant classification within and among databases by unknown
ORIGINAL ARTICLE
Comparison of locus-specific databases for BRCA1 and BRCA2
variants reveals disparity in variant classification
within and among databases
Paris J. Vail & Brian Morris & Aric van Kan &
Brianna C. Burdett & Kelsey Moyes & Aaron Theisen &
Iain D. Kerr & Richard J. Wenstrup & Julie M. Eggington
Received: 18 November 2014 /Accepted: 18 February 2015 /Published online: 18 March 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Genetic variants of uncertain clinical significance
(VUSs) are a common outcome of clinical genetic testing.
Locus-specific variant databases (LSDBs) have been
established for numerous disease-associated genes as a re-
search tool for the interpretation of genetic sequence variants
to facilitate variant interpretation via aggregated data. If
LSDBs are to be used for clinical practice, consistent and
transparent criteria regarding the deposition and interpretation
of variants are vital, as variant classifications are often used to
make important and irreversible clinical decisions. In this
study, we performed a retrospective analysis of 2017 consec-
utive BRCA1 and BRCA2 genetic variants identified from 24,
650 consecutive patient samples referred to our laboratory to
establish an unbiased dataset representative of the types of
variants seen in the US patient population, submitted by cli-
nicians and researchers for BRCA1 and BRCA2 testing. We
compared the clinical classifications of these variants among
five publicly accessibleBRCA1 and BRCA2 variant databases:
BIC, ClinVar, HGMD (paid version), LOVD, and the UMD
databases. Our results show substantial disparity of variant
classifications among publicly accessible databases. Further-
more, it appears that discrepant classifications are not the re-
sult of a single outlier but widespread disagreement among
databases. This study also shows that databases sometimes
favor a clinical classification when current best practice guide-
lines (ACMG/AMP/CAP) would suggest an uncertain
classification. Although LSDBs have been well established
for research applications, our results suggest several chal-
lenges preclude their wider use in clinical practice.
Keywords BRCA1 .BRCA2 . Variant classification .Variants
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Background
The aim of genetic testing is to determine the etiology of a
suspected genetic disorder to influence medical management
or provide a diagnosis that can guide genetic counseling. For
this reason, genetic variants must be classified accurately and
consistently. Professional societies and governmental regula-
tory agencies have provided general guidance regarding the
classification, reporting, and long-term follow-up of variants.
Guidelines for the classification of variants were provided in
2007 by the American College of Medical Genetics and Ge-
nomics (ACMG) (Richards et al. 2008). The ACMG, in col-
laboration with the Association for Molecular Pathology
(AMP) and the College of American Pathologists (CAP), is
currently updating their guidelines towards a more evidence-
based system that provides semi-quantitative guidelines for
variant classification. In publicly circulated near-final drafts
of these guidelines (Lyon et al. 2013; Richards et al. 2014),
the ACMG/AMP/CAP will be recommending a multi-tier
classification system, grouping variants based upon perceived
risk of disease association: pathogenic, likely pathogenic, be-
nign, likely benign, and variant of uncertain significance. The-
se guidelines will recommend that the reporting of novel se-
quence variants from a clinical diagnostic laboratory must
include a clinical interpretation based on the best data avail-
able at the time of testing. In clinical practice, laboratories with
additional gene-specific information and expertise can use
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these guidelines to complement their findings. For example,
our laboratory has previously outlined its approach to variant
interpretation for the BRCA1 and BRCA2 genes (Eggington
et al. 2014).
Locus-specific variant databases (LSDBs) have evolved as
a resource for both researchers and clinicians to interpret the
clinical relevance of genetic sequence variants associated with
Mendelian disorders. The aim of LSDBs is to facilitate variant
interpretation through the use of aggregated data, with variant
specific data and classifications provided by researchers, lab-
oratories, and clinicians. The new ACMG/AMP/CAP se-
quence variant classification guidelines will likely continue
to recommend the cautious use of LSDBs to establish whether
a genetic variant has been reported as associated with disease
(Richards et al. 2008). Recently, a group of researchers and
clinicians evaluated and curated the largest public Lynch syn-
drome (MLH1, MSH2, MSH6, and PMS2) variant database
and demonstrated that the majority of user-submitted clinical
classifications were incorrectly classified within the database
when evaluated by evidence-based standards (Thompson
et al. 2014). This research demonstrates that a cautious use
of LSDBs warrants a thorough review of each database’s
evidence-based methodologies for classification. In addition,
there are many LSDBs available for clinical variant classifi-
cation and it is generally well accepted that differences be-
tween databases exist (Celli et al. 2012; Mitropoulou et al.
2010). However, there has been no comprehensive review to
systematically determine the extent of these discrepancies
and, therefore, the potential impact on clinical classification.
In this study, we undertook a cross-comparison of LSDBs
to measure concordance across and within five publicly ac-
cessible BRCA1 and BRCA2 variant databases. Our aim was
to analyze whether LSDBs provide a consistent classification
for the possible disease association of genetic variants. Our
results show substantial disparity of variant classifications
among and within publicly accessible variant databases. We
also show that the LSDBs in this study failed to provide suf-
ficient evidence to verify the databases’ pathogenic classifica-
tions for less straightforward variant classifications, with the
exception of genetic variants that have been thoroughly char-
acterized in the literature.
Methods
To establish an unbiased dataset for comparison of clinical
classifications within and between public databases, we per-
formed a retrospective database query of BRCA1 and BRCA2
variants identified among consecutive patients who were re-
ferred to Myriad Genetic Laboratories, Inc., for sequencing
and large rearrangement testing in November and December
of 2013 (Fig. 1). Using this snapshot of data as of November
6, 2013, we then cross-referenced each variant in the dataset
with its classification in five publicly accessible databases: (1)
the Breast Cancer Information Core (BIC), an online, open-
access breast cancer mutation database maintained by the Na-
tional Human Genome Research Institute at the National In-
stitutes of Health (NIH) (Szabo et al. 2000); (2) the Leiden
Open Variation Database 2.0 (LOVD, chromium.liacs.nl/
LOVD2/cancer/home.php?select_db=BRCA1, chromium.
liacs.nl/LOVD2/cancer/home.php?select_db=BRCA2),
maintained by the Leiden University Medical Center, the
Netherlands (Fokkema et al. 2011); (3) ClinVar, a freely ac-
cessible public archive maintained by The National Center for
Biotechnology Information (NCBI) at the NIH with the goal
of reporting relationships between human variations and phe-
notypes (Landrum et al. 2014); (4) the BRCA1 and BRCA2
Universal Mutation Database (UMD, http://www.umd.be/
BRCA2/), which contains published and unpublished
information about BRCA1 and BRCA2 mutations reported in
a network of 16 French diagnostic laboratories (Beroud et al.
2000); and (5) the Human Gene Mutation Database (HGMD),
a paid subscription database maintained by the Institute of
Medical Genetics in Cardiff (Stenson et al. 2009).
Variants and their respective classifications in LSDBs were
compiled to analyze discrepancy rates between and within
databases. To facilitate comparison between different classifi-
cation schemes, we grouped classifications within databases
into three major categories: pathogenic (pathogenic and likely
pathogenic), benign (benign and likely benign), and variants
of uncertain clinical significance (VUS). The criteria used for
group classifications from each database are listed in Table 1.
Multiple instances of the same variant, within the same data-
base, were considered as Bconflicting^ if they were assigned
both a pathogenic and benign classification. Classifications
were not considered conflicting within the same database if
a variant was classified as pathogenic and VUS or benign and
VUS. In these cases, the pathogenic or benign clinical
Query BRCA1 and BRCA2 testing




Group variants based on 
inclusion in public databases
as of November 6, 2013
Number of Databases 
Variants listed in:
One or more: 1,327
Two or more: 931
Three or more: 633
Four or more: 328
All Five: 124
Fig. 1 Flow diagram of the study design showing BRCA1 and BRCA2
variants identified for study due to detection in the sequencing of 24,650
consecutive patient samples presumed to be unrelated or only distantly
related. The number of unique variants among these patients and the
number of these variants shared across the BIC, ClinVar, HGMD (paid
version), LOVD, and UMD databases are represented
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classification was used in cross-database comparisons. The
variants with classifications that were found in the BOther
Classifications^ category were excluded from the comparison.
For quality assurance of the data, once the classifications in
the data set were recorded, a blinded reviewwas performed by
two independent reviewers who were given a list of 100 var-
iants from the overall dataset. These 100 variants were ran-
domly selected in order to obtain a representative subset of the
variants analyzed here. Each reviewer queried all five data-
bases, noting the classification if available. Once the review
was complete, the subset of variants was compared to the
initial list of classifications to verify their accuracy. This ap-
proach allowed for the discovery and correction of any sys-
tematic errors, which arose primarily from inconsistent no-
menclature across databases.
Agreement across databases
To investigate the degree to which LSDBs agree on variant
classifications, we stratified the 2017 unique variants based on
the number of databases in which they were present (e.g., all
variants that were seen in four databases formed one group).
For each database in which a variant occurred, its classifica-
tion was noted. Agreement was defined as all LSDBs in which
a variant occurred assigning the same classification. The fre-
quency of agreement (%) was calculated as the number of
variants where agreement was found against the number of
variants assigned the specified classification in one or more
databases (for sample sizes in the different categories, see
Fig. 2). For example, a variant was judged to be in the
Bpathogenic^ subset if at least one database assigned that clas-
sification. We recorded this agreement separately for all vari-
ants judged to be pathogenic, benign, and VUS.
Discrepancies within databases
We also examined the potential for conflicting variant classi-
fications to occur within the same database. BIC, HGMD, and
UMD provide a single Bmaster^ clinical classification per
unique variant on the primary variant report page; however,
ClinVar and LOVD currently do not provide a single Bmaster^
classification and instead list the conflicting entries. The var-
iants with conflicting entries in these databases are listed in the
Supplemental Material. We totaled the number of variants
seen for each classification (pathogenic, benign, VUS) in each
of the five LSDBs and recorded the conflicting classifications
when multiple instances of the exact same variant were ob-
served in the same database.
Analysis of additional evidence utilized by databases
The use of literature and unique empirical data is an important
facet of variant classification. However, the clinical utility of
such information may be subject to debate when, e.g., the raw
data are unavailable to support a reported conclusion or an
intermediate functional effect is reported in a biochemical as-
say. To assess the use of literature and unique empirical data
by LSDBs, we first collected a subset of variants from the 124
unique variants found in all five LSDBs that could be conser-
vatively classified as VUS. The following criteria were used to
select this subset: (1) variant listed in all five of the databases,
(2) variant receives a default classification of VUS when ex-
cluding literature and other empirical evidence, and (3) defin-
itively classified by at least one of the five databases as path-
ogenic (or likely pathogenic). The draft form of updated
guidelines from the ACMG/AMP/CAP Interpretation of Se-
quence Variations Workgroup was used for this analysis
Table 1 Definitions of clinical classifications for comparison across databases
BIC ClinVar HGMD LOVD UMD









Uncertain (VUS) BClinically important—unknown^ BVariant of unknown significance^
BRisk factor^
N/A B?/?^ B3—UV^










Other classifications None BNot provided^
BConflicting data from submitters^
None None B−^
Classifications for HGMD are defined as follows: BDM^ is a disease causing (pathological) mutation, BDM?^ is a likely disease causing (likely
pathological) mutation, BFTV^ is a frameshift or truncating variant with no disease association reported yet, BFP^ is a polymorphism affecting the
structure, function or expression of a gene but with no disease association reported yet, BDP^ is a disease associated polymorphism, BDFP^ is a disease
associated polymorphism with additional supporting functional evidence (Stenson et al. 2009). Classifications for LOVD are defined as follows: B+^ is
pathogenic, B+?^ is probably pathogenic, B?^ is effect unknown, B-^ is no known pathogenicity, and B-?^ is probably no pathogenicity. All classifications
are listed in the format BReported/Concluded^, although for all variants in this data set, the Concluded classification was B?^ (Fokkema et al. 2011). A
VUS classification in UMD is defined as B3—UV ,^ referring to Buncertain variant^ (Beroud et al. 2000).
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(Table 3). To establish a default VUS classification for criteria
#2, the following types of variants were considered: missense
variants, intronic variants greater than two nucleotides inside
the intron from the native RNA splice acceptor or donor site,
in-frame insertions/deletions, and variants within the 5' un-
translated region (UTR). We next noted the reported
classification of these variants in the five LSDBs and plotted
all pathogenic and benign classifications (Fig. 3). Any variants
that already held a VUS clinical classification in a given da-
tabase were excluded from further analysis.
We also evaluated the content of the BIC, ClinVar, LOVD


































































































Fig. 2 Agreement between
database classifications of
variants from an unbiased set of
2017 BRCA1 and BRCA2 unique
genetic variants identified in
patients. The proportion of
agreement is presented according
to the number of databases in
agreement (x-axis) for (a) all
databases examined (BIC,
ClinVar, HGMD, LOVD, and
UMD) and (b) all databases
except HGMD, which had the
highest degree of discrepancy.
Variants listed in all databases as
pathogenic and likely pathogenic
were grouped into the
Bpathogenic^ subset (red).
Variants listed in all databases as
benign or likely benign were
grouped into the Bbenign^ subset
(blue). BVUS^ (grey) represents
variants for which all databases
described assigned a classification
of variants of uncertain
significance
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sufficient, verifiable supporting data for an independent re-
viewer to concur with the databases’ pathogenic classification.
As HGMD had the highest discrepancy rate when all data-
bases were compared, it was excluded from this analysis. To
perform this analysis, we chose a set of Bchallenging to
classify^ variants, which we defined as variants present in
all four databases (BIC, ClinVar, LOVD, and UMD) that
would be conservatively classified as VUS per the criteria
listed previously but that were classified as Bpathogenic^ in
one ormore databases. The evidence listed in the database was
then evaluated using the evidence-based criteria released in
draft form by the ACMG/AMP/CAP Interpretation of Se-
quence VariationsWorkgroup, which are soon to be published
(Lyon et al. 2013; Richards et al. 2014). Sufficient supporting
data was defined as verifiable data contained or referenced in
the database that met the minimal requirements for a BLikely
Pathogenic^ classification (note—for the purposes of this
evaluation, a variant’s listing in a public database was not used
as a supporting line of evidence for classification).
Results
During the 2-month study period (Nov–Dec 2013), we eval-
uated the variants identified in 24,650 consecutive patient
samples referred to our laboratory for sequencing and large
rearrangement testing in the BRCA1 and BRCA2 genes. From
these patient samples, we obtained 2017 unique BRCA1 and
BRCA2 variants among the study population. We then catego-
rized these variants by the number of databases in which they
were identified. Of the 2017 unique finds, 1327 were present
in one or more databases, 931 were present in two or more
databases, 633 were present in three or more databases, 328
were present in four or more databases, and 124 were present
in all five databases (Fig. 1).
Agreement across databases
The ability of multiple LSDBs to agree on a given variant
classification is illustrated in Fig. 2a. For pathogenic and
VUS classifications, it is clear that the level of agreement con-
sistently decreases as more database evaluations are added. For
VUSs in particular, there is no agreement once the variant is
observed in a least four of the five databases in this study.
Although the percentage agreement increases slightly when a
Bbenign^ variant is observed in three databases, it falls off again
when observed in four. Figure 2b illustrates the agreement
analysis, excluding HGMD which had the highest rate of dis-
crepancy, and shows the same general trend as Fig. 2a.
Discrepancies within databases
Of the 2017 variants evaluated in this study, ClinVar contained



















Fig. 3 Analysis of the LSDB clinical classifications (benign or
pathogenic) of variants considered BVUS^ by the criteria outlined in the
BMethods^ section. Sixty-three of the 124 unique variants shared across
the BIC, ClinVar, HGMD (paid version), LOVD, and UMD databases
met these criteria. To determine how LSDBs vary in their treatment of
these Bchallenging to classify^ variants, we compared the clinical
classifications of each BVUS^ in all five databases. Variants with con-
flicting entries of VUS and either pathogenic or benign in the same data-
base are categorized as either pathogenic or benign in the figure (see
Table 1). Variants with conflicting classifications of both pathogenic
and benign in the same database were excluded from this figure
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(Table 2). LOVD contained 470 variants with 61 assigned
conflicting classifications. These results indicate that when
differing classifications are allowed within a database, as is
the case for ClinVar and LOVD, discrepancies in clinical clas-
sifications may occur.
Analysis of additional evidence utilized by databases
Of the 124 variants shared across all five LSDBs, 63 variants
would be conservatively classified as VUS according to the
simplified guidelines outlined in the BMethods^ section. How-
ever, Fig. 3 illustrates that different databases vary significant-
ly in the reported clinical classification for these variants when
additional evidence is considered (i.e., literature and unique
empirical data). Our results show that HGMD favors patho-
genic clinical classifications for 61 of 63 variants in this subset
that other databases classify as either VUS or benign (note—
HGMD currently states on its Frequently Asked
Questions (FAQ) webpage that its current database is contam-
inated with variants listed as pathogenic that are now known
to be benign and that Bto resolve this issue is likely to be a
slow iterative process.^).
Within the subset of 63 variants identified, 18were found that
could be considered Bchallenging to classify^ (Table 3). Among
these 18 variants, without exception, those with sufficient em-
pirical data to support the LSDB pathogenic classifications were
those that had been published in peer-reviewed literature. In this
subset, UMD and LOVD performed the best in supporting their
pathogenic classifications through the use of appropriate litera-
ture references (71 % and 40 % of the pathogenic claims, re-
spectively) (Table 3). BIC and ClinVar performed equally poor-
ly, both failing to support any of the pathogenic classifications
with empirical evidence at the time of this study.
Of special note, in Table 3 are the conflicting classifications
for BRCA1 c.5408G>C (p.Gly1803Ala) between LOVD and
UMD. The latter classifies the variant as pathogenic and the
former as benign. The two databases provide overlapping lit-
erature citations to support their classifications. However,
while UMD classifies the variant as pathogenic, the comments
listed for the literature cited in the variant information suggest
that the variant is trending towards a benign classification. The
pathogenic classification is therefore likely to be a data entry
error or an instance where incomplete information is provided
to support the given classification. Similar differences were
discovered in other databases. For example, a LOVD entry
for the well-characterized pathogenic mutation BRCA1
c.181T>G (p.Cys61Gly) is listed as benign (Caligo et al.
2009; Goldgar et al. 2004). Also discovered were likely data
entry errors for two of the 18 variants in Table 3, which were
submitted to ClinVar through the Sharing Clinical Reports
Project (see Table 3 footnotes). Collectively, this highlights
the importance of reviewing all available literature and
supporting information regarding a variant classification be-
fore issuing a clinical report, as database classifications can be
discordant and incomplete.
Discussion
Accurate and consistent data curation is critical to the value
derived from LSDBs in categorizing the relationship between
genetic variation and disease, particularly for clinical applica-
tions. In this study, we performed a retrospective analysis of
2017 BRCA1 and BRCA2 variants identified in our laboratory.
We compared the clinical classifications of these variants
across BIC, ClinVar, HGMD (paid version), LOVD, and
UMD to determine whether LSDBs provide a consistent clin-
ical classification.
Our results show substantial disparity of variant classifica-
tions among databases. In our evaluation, it was rare for all
five databases to agree on variant classification. For example,
of 116 variants present in all five databases that received a
classification of Bpathogenic^ in at least one database, only
four variants were classified as pathogenic in all five databases
(Fig. 2a). Even when the outlier database (HGMD) was re-
moved from the comparison, this did not mitigate the de-
creased level of agreement we observed as more databases
are considered. These results not only highlight an absence
of increased accuracy when a variant is observed in multiple
databases but also the disparity in classification schemes used
across LSDBs. Although two thirds of the variants identified
in the patient samples were listed in one or more BRCA1 and
BRCA2 databases, the remainders were not listed in any
LSDB, likely owing to their rarity.
Table 2 Discrepancies within BRCA1/BRCA2 databases for the 1327
variants evaluated
BIC ClinVar HGMD LOVD UMD
A Bmaster^ classification
is assigned
Yes No Yes No Yes
Pathogenic classifications 305 172 536 62 201
Benign classifications 84 172 12 256 199
VUS classifications 645 93 0 91 434
Conflicting classifications N/A 18 N/A 61 N/A
Total unique variants 1034 455 548 470 834
356 J Community Genet (2015) 6:351–359
Table 3 Evaluation of the supporting data provided in BRCA1/2 databases for the pathogenic classification of 18 challenging variants as measured by
evidence-based guidelines for variant interpretation of Blikely pathogenic^(Lyon et al. 2013; Richards et al. 2014)
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Two of the five evaluated databases do not provide a
Bmaster^ clinical classification and allow for internal database
conflicts (pathogenic and benign) for the same variant. These
conflicts limit the overall utility of LSDBS and highlight the
inconsistent methodologies used to populate the database.
As information from genetic testing may be used to make
important clinical decisions that may involve prophylactic
surgery, the ACMG/AMP/CAP guidelines recommend a con-
servative and evidence-based approach to variant interpreta-
tion, with the goal of avoiding speculation. When sufficient
data is absent for an evidence-based classification, the guide-
lines recommend classifying variants as having uncertain clin-
ical significance. However, it is important to note that all
public databases included in our analysis contain a dis-
claimer that the database is to be used for research pur-
poses only. Our findings illustrate that some public data-
bases frequently lean more towards aggressive classifica-
tion when evidence-based protocols indicate that, in a clin-
ical setting, a VUS classification would be more appropri-
ate for particular variants.
For an unbiased subset of 18 variants evaluated in this
study, application of these evidence-based guidelines to
existing US government-sponsored and international-based
BRCA1 and BRCA2 databases shows that the BIC, ClinVAR,
LOVD, and UMD databases failed to provide sufficient veri-
fiable content, independent of published literature, to achieve
evidence-based verification of their listed Bpathogenic^
classifications. This might suggest that the use of a database
that relies solely upon literature references would be more
prudent, such as the use of HGMD. Yet, as described on the
HGMD FAQ web page, this database is known to be signifi-
cantly contaminated with Bpathogenic^ variants classified in
the literature as benign. This information correlates with our
findings that HGMD variant classifications were frequent out-
liers (Fig. 3). However, not all literature used to support a
LSDB’s pathogenic classification provided sufficient evi-
dence to meet the evidence-based standards for Blikely
pathogenic.^ This underscores the need for users to indepen-
dently evaluate referenced literature. Interestingly, even when
published literature provided sufficient evidence for a patho-
genic classification, the four databases failed to show concor-
dance in the use of the best available literature.
Recently, Thompson et al. reported an evaluation of the
LOVD-hosted InSIGHT database for mismatch repair variants.
In this analysis, the application of evidence-based criteria re-
sulted in the reclassification of 66 % of the eligible variant
entries, including the reversal of pathogenic classifications to
benign and vice versa (Thompson et al. 2014). Considering that
most public LSDBs do not include a user-tracking mechanism,
it is unlikely that the laboratories, clinicians, and patients who
previously used the incorrect, non-evidence-based classifica-
tions were actively notified of the variant reclassifications. This
poses a significant challenge and burden for the user of public
LSDBs that has not yet been resolved.
Table 3 (continued)












BPathogenic^ or BVUS^ refers to the classification made in the associated database for the variant according to the groupings defined in Table 1. For
variants listed as pathogenic, Bdata^ describes the type of data provided in the associated database to support the classification. BSufficient^ or
Binsufficient^ represents whether or not the supporting data provided or referenced by the database is verifiable and meets the minimal requirements
for a Blikely pathogenic^ classification according to ACMG/AMP/CAP evidence-based criteria (Lyon et al. 2013; Richards et al. 2014)
a Classification was submitted to ClinVar from the Sharing Clinical Reports Project (http://sharingclinicalreports.org/), but no supporting evidence
provided in the ClinVar display
bAt the time of the initial ClinVar evaluation (November 6, 2013), ClinVar database did not provide supporting data for the clinical classification.
However, at the time of manuscript preparation (March 11, 2014), the database listed an additional entry for the variant, which lacked a clinical
classification, but did provide literature references which did not provide sufficient verifiable evidence required to meet minimal ACMG standards
for at least a likely pathogenic classification
c LOVD listed both pathogenic and uncertain classifications (see Table 1) for this variant where the literature associated with the uncertain classification
did provide sufficient verifiable evidence to meet minimal ACMG standards for a likely pathogenic classification, but the literature associated with the
listed pathogenic classification did not meet these standards
d UMD frequently provides the age of disease onset in anonymized patients who have been reported by UMD’s contributors as carrying the variant.
However, for the variants reported here, literature references were the primary data source for variant classification
e Same as table footnote Bb^ for ClinVar, except that the entry added after our initial evaluation listed literature references which did meet minimal
ACMG standards for a likely pathogenic classification, though the added entry did not provide a clinical classification
f The database lists a pathogenic classification, but the supporting data trends for a contrary (benign) classification
g ClinVar displays the most recent classification submitted from the Sharing Clinical Reports Project. At the time of the initial ClinVar evaluation
(November 6, 2013), ClinVar database displayed a Bpathogenic^ classification^ from the Sharing Clinical Reports Project. At the time of manuscript
preparation (March 11, 2014), ClinVar displayed a Bbenign^ or Blikely benign^ classification from the Sharing Clinical Reports Project
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The ability for laboratories to provide sufficient patient- and
family-specific data in public databases is challenging because
of country-specific laws protecting personal health information.
To counter this, databases that attempt to provide empirical data
often simplify complex phenotype/genotype information in ef-
forts to anonymize the data for data sharing. However, such
simplified data may be misleading. In BRCA1 and BRCA2
LSDBs in which only the proband disease status is provided
(e.g., UMD), ascertainment bias must be considered in all as-
sessments as the majority of tested patients are being selected
for breast and/or ovarian cancers; thus, truly benign variants
may seem to be associated with disease because of this bias.
It is therefore critical to develop and use clinically validated
methods that rely on rigorous control matching to account for
this bias (Eggington et al. 2014; Pruss et al. 2014).
Conclusions
This analysis presents a systematic evaluation of several com-
monly used LSDBs and their limitations in clinical variant
classification. Our results show substantial disparity of variant
classifications among and within publicly accessible variant
databases. Although LSDBs have been well established for
research applications, our results suggest that several chal-
lenges inhibit their wider use in clinical practice. Healthcare
providers should exercise caution when using these research
tools for clinical purposes. With so many BRCA1/2-specific
databases now available, it is a challenge to identify the most
updated and accurate resources. The number of available da-
tabases also presents the challenge of curating the often con-
flicting variant classifications available (Celli et al. 2012;
Mitropoulou et al. 2010). We recommend that for any test that
may result in definitive and irreversible clinical intervention,
the laboratory issuing the genetic report should carefully eval-
uate each piece of data used for variant classification.
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